Biological activity of the IL-1 system depends on the balance between two proinflammatory proteins (IL-1a and IL-1b) and the related anti-inflammatory protein, the IL-1 receptor antagonist (IL-1Ra). The genes for these proteins lie within 430 kb on human chromosome 2. Based on a clinical trial of human recombinant IL-1ra in rheumatoid arthritis, we tested whether IL-1 genotype might be related to the likelihood of response to anti-IL-1 therapy. A positive response was defined as a reduction of at least 50% in the number of swollen joints by week 24, following treatment with either 150 mg/day IL-1ra or placebo. The response rate to treatment, independent of genotype, was 48% (44/91). A highly significant association was found between carriage of the rarer allele at IL1A( þ 4845) and response to treatment (P ¼ 0.0009; OR ¼ 4.85 (1.85,12.70)). The response rate in patients carrying this allele was 63.4% compared with 26.3% in noncarriers. A weaker association was found for IL1B( þ 3954) (P ¼ 0.02). There was a highly significant interaction between treatment (150 mg/day or placebo) and the composite genotype across IL1A( þ 4845) and IL1B( þ 3954) (P ¼ 7.6 Â 10
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that leads to bone and cartilage destruction by inflammatory mediators including cytokines and metalloproteinases. 1 The proinflammatory cytokines interleukin-1 (IL-1) and tumour necrosis factor alpha (TNF-a) have been implicated in the disease process. [2] [3] [4] Interleukin-1 alpha (IL-1a) and IL-1b are agonist molecules of the IL-1 system that activate target cells by binding to the type 1 IL-1 receptor. 5 A third molecule, the IL-1 receptor antagonist (IL-1ra), is a potent endogenous anti-inflammatory protein that blocks the binding of IL-1a and b to the receptor. Deletion of the IL-1ra gene in mice results in a symmetrical synovitis resembling rheumatoid arthritis 6 and IL-1 antagonists are beneficial in animal models of RA. 7, 8 The efficacy of human recombinant (hr) IL-1ra in the treatment for RA was first shown in a clinical trial, where 43% of patients receiving hrIL-1ra (150 mg/day for 24 weeks) showed improvement according to ACR criteria compared with 27% in the placebo group. 9 The genes encoding the three IL-1 proteins have been mapped to a 430 kb region on chromosome 2. 10, 11 Single nucleotide polymorphisms (SNPs) and other variations have been identified in each of the genes, and linkage disequilibrium across the region leads to the presence of common haplotypes in the population. 12 Polymorphisms of the IL-1 region have been related to stable interindividual differences in IL-1 production 13 and associated with susceptibility to common inflammatory diseases, including the more erosive form of rheumatoid arthritis. [14] [15] [16] Based on the association between IL-1 genotype and susceptibility to RA, our hypothesis was that responsiveness to hrIL-1ra might also be affected by IL-1 genotype. The aim of the present study was to test this hypothesis in a randomised clinical trial of hrIL-1ra in patients with RA. In view of the role of TNF (chromosome 6p21) as a treatment target in RA, 17 we also investigated whether interactions between IL-1 and TNF-a genotypes might affect the response. Our analysis aimed at identifying the primary effects (as distinct from those due to linkage disequilibrium), and interactive effects that might be predicted either from competition between the IL-1 proteins for binding to the IL-1 receptor, or the shared involvement of TNF and IL-1 in the inflammatory response pathway.
Results

v
analyses
The overall response rate using the 50% reduction in swollen joint criterion in the unstratified treatment group receiving 150 mg/day IL-1ra was not significant (48.4%, compared with 37.6% for placebo (P ¼ 0.1519)). Table 1 shows the results for the five IL-1 polymorphisms and TNFA(À308). A significant result was found both for the IL1A( þ 4845) and the IL1A(À889) polymorphisms suggesting a four to five fold increase in response rate to 150 mg IL-1ra when an individual carried the rarer allele (P ¼ 0.0009 and 0.0018, respectively). A borderline significant result was found for IL1B( þ 3954), where again carriage of the rarer allele increased response (P ¼ 0.02). Previously we have shown that these three alleles lie on a common haplotype. 12 Results for IL1B(À511), IL1RN( þ 2018), and TNFA(À308) were not significant.
No significant associations between response and genotype at IL-1A( þ 4845), IL-1A(À889), or IL-1B( þ 3954) were found in patients who received placebo.
Decision tree analysis Figure 1 shows the decision tree. As expected, IL1A( þ 4845) was selected as the first variable to distinguish response rates based on carriage of the rare allele. At the second level of the tree, a borderline significant result is seen for IL1B( þ 3954). Although this result is not significant (probably due to small sample size), it suggests that IL1B( þ 3954) may increase the response rate for those individuals who do not carry the rarer allele at IL1A( þ 4845). However, there was no evidence for a branch for IL1B( þ 3954) from the 'IL1A( þ 4845): carriage allele 2' node, indicating that if an individual already carried the rarer allele at IL1A( þ 4845), then that carriage of the rarer allele at IL1B( þ 3954) did not increase response rates. As a further exploration of this result, we performed another analysis where we forced the tree to split initially for the variable IL1B( þ 3954), and then grew the tree freely thereafter (data not shown). In this case, a significant result was found for IL1B( þ 3954) (P ¼ 0.01), and a second level of the tree was grown from the 'IL1B( þ 3954): 11' node, based on carriage of the rarer allele at IL1A( þ 4845) (P ¼ 0.0014). Again, there was no evidence for a branch necessary from the 'IL1B( þ 3954): carriage allele 2' node. No significant branches were observed for IL1A(À889). Hence, these results indicate that the previous significant result for IL1A(À889) was probably due to linkage disequilibrium with IL1A( þ 4845), which is not surprising since these polymorphisms are only 5.7 kb apart. In addition, this analysis indicates tentative evidence that carriage of the rarer allele at either IL1A( þ 4845) or IL1B( þ 3954) increases the response rate to 150 mg of IL-1ra.
Logistic regression: investigating treatment Â genetic interactions Logistic regression analysis was performed to investigate further the possible interaction between treatment and genotype at the IL-1 locus. We chose to use the composite genotype suggested above, that is, carriage of the rarer allele at IL1A( þ 4845) or IL1B( þ 3954), compared to all other genotypes, as the genetic factor in the analysis. Two treatments were considered: those on 150 mg/day hrIL1-ra and those given the placebo. Response (as described previously) was used as the dependent variable, and the genotype, treatment and an interaction variable were the three independent variables used in the analysis. The results indicated a highly significant interaction between treatment and genetic variables (P ¼ 7.6 Â 10 À5 ). Hence, we investigated the effect of treatment (150 mg/ day or placebo) in the two genetic groups separately. In the 'high responder' genetic group (carriage of the rare allele at IL1A( þ 4845) or IL1B( þ 3954)), there was a significant association between treatment and response (P ¼ 0.0025), with those on 150 mg/day responding at a higher rate (OR ¼ 4.03, 95% CI [1.60,10.17]). However, there was no significant association found between treatment with 150 mg/day rhIL-1ra and response in the complement genetic group (P ¼ 0.20). Figure 2 illustrates the rates of response for treatment and placebo across the two genetic groupings.
Discussion
The results indicate that IL-1 genotypes influence reduction in swollen joints in RA patients treated with 150 mg/day of human recombinant IL-1ra, whereas genotype at TNFA(À308) does not. Specifically, we found that the response rate in patients carrying the rarer allele at IL1A( þ 4845) was 63.4% compared with 26.3% in noncarriers. In addition, we found tentative evidence that the increase in response is maintained if a patient does not carry the rarer allele at IL1A( þ 4845) but does carry the rarer allele at IL1B( þ 3954). We further investigated this finding using logistic regression and illustrated a highly significant interaction between treatment and the composite genotype (P ¼ 7.6 Â 10 À5 ). This interaction was not significant for IL1A( þ 4845) Pharmacogenomic response to IL-1ra in RA NJ Camp et al alone (data not shown), adding further evidence that the composite genotype was important. We tested all positive findings in patients receiving a placebo. Results were not replicated in this sample. These results and those of the logistic regression suggest that we are, therefore, measuring a true pharmacogenomic effect. We have also tested the effect of these genotypes at lower doses of IL-1ra, and using the ACR improvement criterion as the outcome measure. Similar trends were seen as those shown here, although the results were not statistically significant (data not shown). Further large studies will be required to confirm the pharmacogenomic effect of IL-1 polymorphism, in particular to investigate the genetic interaction between IL1A( þ 4845) and IL1B( þ 3954), since the more common haplotypes across the IL-1 cluster contain either both the rarer alleles at these positions, or both the common alleles. 12 Functional studies will also be required to demonstrate the role of these polymorphisms in IL-1 biology in the inflamed joint. Many studies have reported associations between carriage of the rarer alleles at IL1A( þ 4845) or IL1B( þ 3954) and increased susceptibility to several inflammatory diseases including RA, [14] [15] [16] Alzheimer's Disease, 18 and periodontitis. 19 In addition, other studies Pharmacogenomic response to IL-1ra in RA NJ Camp et al have related IL1A( þ 4845) or IL1B( þ 3954) polymorphisms to altered IL-1 production, 13, 20, 21 and it has also been suggested that genotype at IL1B may influence IL-1ra levels and vice versa. 22, 23 Our findings here further extend the involvement of the IL-1 gene cluster with the inflammatory response and suggest that treatment with a specific antagonist, IL-1ra, may be optimal only in a subset of patients where the IL-1 system plays a major role in the pathogenesis. This implies a previously unknown level of genetic heterogeneity in RA. In agreement with published data, 49.5% of the 426 individuals genotyped in this study carried the rare allele at IL1A( þ 4845), and 53.5% carried the composite genotype. 16 All these data suggest that the rarer alleles themselves (or others in linkage disequilibrium with them) influence the balance of agonist (IL1a and IL1b) and antagonist (IL-1ra) molecules of the IL-1 system in a way that alters susceptibility to inflammatory disease. There are, of course, many other cytokines involved in the inflammatory response, and our findings here may form only the first piece of a much more complex picture involving other cytokines also. This is illustrated by recent data, which show that the subset of patients that do not respond to TNF-a blockade may also not respond to Anakinra. [24] [25] [26] The present study indicates that ascertainment of IL-1 genotype in RA patients may identify individuals more likely to be in the subgroup of high responders to rhIL1ra. It seems possible, if not likely, that a similar subgroup of high responders to IL-1 antagonism might exist in other diseases, where IL-1 genotype has been associated with disease susceptibility. Further, similar principles are likely to apply to many therapies, especially the newer biological medicines that target specific genetic pathways. Genomics and proteomics are used extensively to identify drug targets and in these cases the genetic basis of drug action is known from the outset. Our results suggest that pharmacogenomic studies should be carried out to investigate differences in response to these treatments.
Many other factors, apart from increase in response, need to be taken into account when considering the role of pharmacogenomic observations in the context of drug development or medical practice. They include treatment side effects, invasiveness and costs of treatment and testing, and the overall risk/benefit to individuals and cost/benefit to drug developers and health care providers. However, advances in genomics are likely to have an increasing impact on the clinical use of drugs, in terms of both pharmacokinetics and, as in this report, the pharmacodynamic response. As the evidence for pharmacogenomic associations is now compelling, 27 it is important that we formulate principles to decide which, if any, warrant development into pre treatment genetic tests.
Patients and methods
Patients and study design A full description of the clinical trial is given by Bresnihan et al. 9 Patients were recruited from 41 centres in 11 European countries and included in the study if they met the American College of Rheumatology (ACR) criteria for RA, 28 and had symptoms for between 6 months and 8 years. Treatment was by daily selfadministered subcutaneous injection of recombinant IL-1ra (Amgen Inc., CA, USA) for 24 weeks. Data were available on 472 patients that had been randomised into four groups: placebo (n ¼ 121), IL-1ra 30 mg/day (n ¼ 119), IL-1ra 75 mg/day (n ¼ 116), IL-1ra 150 mg/day (n ¼ 116). In the present study, we analysed the highest dose arm of the trial (150 mg/day) against the efficacy end point of X50% reduction in number of swollen joints by week 24. This was chosen as being more likely to be related to active inflammation, and therefore to IL-1 and TNF, than the more indirect or composite measures such as the health assessment questionnaire or ACR composite score.
Data were available on 91 patients treated with 150 mg/day; however, DNA was available only from 80 in this group, and from 104 individuals treated with placebo.
Genotyping
We genotyped five SNPs in the IL-1 cluster; IL1A( þ 4845) and (À889), IL1B( þ 3954) and (À511), and IL1RN( þ 2018) and one polymorphism in TNFA(À308). Genotyping was by PCR-RFLP using validated protocols that have been described in detail previously. 29 
Statistical methods
Three types of analyses were performed: w 2 analysis, decision tree analysis using AnswerTree v 2.0.1 (SPSS Inc.) and logistic regression. w 2 analyses were performed to identify polymorphisms that were associated with a positive response of at least a 50% decrease in the number of swollen joints. Decision tree analysis was used to explore the possibility of interactions between the effects of the different polymorphisms, with the objective of distinguishing linkage disequilibrium from epistatic effects. This is important since there is moderately strong linkage disequilibrium across the 430 kb IL-1 region, 12 and the three IL-1 gene products are functionally related. The method of Exhaustive w 2 Automatic Interaction Detector was used. Response to treatment was used as the target (dependent) variable and carrier status of the rarer allele at each of the five IL-1 polymorphisms and TNFA(À308) as indicator (independent) variable. Where interactions were indicated, logistic regression analysis for response was used to further investigate the interaction between treatment and response.
